Propynylated phosphodiester oligonucleotides inhibit ICAM-1 expression in A549 cells on electroporation

Antisense & Nucleic Acid Drug Development
L MeunierA C Roche

Abstract

Oligodeoxynucleotides (ODN) are used largely as either primers, antisense, or triplex-forming units. Phosphodiester ODN (PO-ODN), which are very rapidly degraded by exonucleases, must be protected at their ends. Even so, their life span inside cells is quite short. Phosphorothioate ODN (PS-ODN) are less sensitive to nucleases and are extensively used as antisense. Unfortunately, unlike PO-ODN, they interact with a number of molecules, including proteins, in addition to their specific nucleic acid targets. Their affinity for their target is lower than that of PO-ODN. PS-ODN containing propyne groups on C5 of pyrimidine have been shown to have a higher affinity toward their nucleic acid target. Here, we show that propynylated PO-ODN are more stable and much more efficient than their propyne-free counterparts. They are not efficient when they are used as lipoplexes, but they act as specific antisense on electroporation.

References

Apr 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·J P LeonettiB Lebleu
Dec 17, 1982·Journal of Immunological Methods·G D JohnsonE J Holborow
Jun 1, 1995·Current Opinion in Structural Biology·A De MesmaekerS Wendeborn
Jan 1, 1995·Journal of Virology·K RaviprakashM Carl
Jun 29, 1994·Biochimica Et Biophysica Acta·V V VlassovL A Yakubov
Jul 9, 1993·Journal of Medicinal Chemistry·J F MilliganJ C Martin
Apr 16, 1996·Proceedings of the National Academy of Sciences of the United States of America·A M GewirtzP M Glazer
Apr 16, 1996·Proceedings of the National Academy of Sciences of the United States of America·J G LewisR W Wagner
Jan 1, 1996·Annual Review of Pharmacology and Toxicology·S T Crooke, C F Bennett
Aug 1, 1997·Antisense & Nucleic Acid Drug Development·C PichonA C Roche
May 21, 1998·Antisense & Nucleic Acid Drug Development·S T Crooke
Sep 1, 1996·Nature Biotechnology·W M FlanaganR W Wagner
Jan 25, 2000·Antisense & Nucleic Acid Drug Development·S DheurE T Saison-Behmoaras
May 11, 2000·Antisense & Nucleic Acid Drug Development·F Eckstein

❮ Previous
Next ❯

Citations

Dec 7, 2002·The International Journal of Biochemistry & Cell Biology·Ramareddy V GuntakaKarl T Weber

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.